Antibody dissociation rates are predictive of neutralizing antibody (NAb) course : a comparison of interferon beta-1b-treated Multiple Sclerosis (MS) patients with transient versus sustained NAbs

Copyright © 2014 Elsevier Inc. All rights reserved.

Détails bibliographiques
Publié dans:Clinical immunology (Orlando, Fla.). - 1999. - 157(2015), 1 vom: 28. März, Seite 91-101
Auteur principal: Gibbs, Ebrima (Auteur)
Autres auteurs: Karim, Mohammad Ehsanul (Autre), Oger, Joel (Autre), Steering Committee of the BENEFIT study (Autre), Edan, Gilles (Autre), Freedman, Mark S (Autre), Hartung, Hans Peter (Autre), Miller, David (Autre), Montalbán, Xavier (Autre), Pleimes, Dirk (Autre), Pohl, Christoph, Polman, Chris, Sandbrink, Rupert
Format: Article en ligne
Langue:English
Publié: 2015
Accès à la collection:Clinical immunology (Orlando, Fla.)
Sujets:Clinical Trial Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't Antibody dissociation rate; Biacore™ Immunogenicity; Interferon beta; Multiple sclerosis; Transient and sustainedneutralizing antibody; plus... Antibodies, Neutralizing Interferon beta-1b 145155-23-3 Interferon-beta 77238-31-4